Keyword Analysis & Research: bolt biotherapeutics


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
bolt biotherapeutics0.450.137901720
bolt1.620.62132534
biotherapeutics1.550.271509715

Keyword Research: People who searched bolt biotherapeutics also searched

Keyword CPC PCC Volume Score
bolt biotherapeutics0.660.2254433
bolt biotherapeutics stock1.240.6832875
bolt biotherapeutics news1.80.4212868
bolt biotherapeutics aktie0.590.7838796
bolt biotherapeutics careers0.250.5199329
bolt biotherapeutics ir0.911821966
bolt biotherapeutics ipo0.710.1532426
bolt biotherapeutics linkedin1.370.5798797
bolt biotherapeutics wikipedia1.330.7630897
bolt biotherapeutics market cap0.080.8859329
bolt biotherapeutics stock price0.980.9849350
bolt biotherapeutics redwood city0.680.6384434
bolt biotherapeutics inc1.960.5982673
(Choose at least 2 and not exceed 5 keywords)

Choose at least 2 and not exceed 5 keywords


Search Results related to bolt biotherapeutics on Search Engine

  • Bolt Biotherapeutics - Unleashing the power of the immunity system

    boltbio.com

    https://www.boltbio.com/

    WEBBolt Biotherapeutics is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

    DA: 41 PA: 76 MOZ Rank: 87

  • About Us - Bolt Biotherapeutics

    boltbio.com

    https://www.boltbio.com/about/

    WEBBolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area. Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug …

    DA: 51 PA: 60 MOZ Rank: 85

  • Pipeline - Bolt Biotherapeutics

    boltbio.com

    https://www.boltbio.com/pipeline-new/

    WEBLearn More About BDC-3042. View Publications. View the robust Bolt Biotherapeutics pipeline of immune-stimulated, myeloid-engaging therapeutics.

    DA: 27 PA: 70 MOZ Rank: 23

  • Bolt Biotherapeutics, Inc. (BOLT) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/BOLT/

    WEBBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001...

    DA: 35 PA: 87 MOZ Rank: 15

  • Corporate Overview - Bolt Biotherapeutics

    boltbio.com

    https://investors.boltbio.com/

    WEBNov 14, 2023 · Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development.

    DA: 23 PA: 63 MOZ Rank: 37

  • Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study

    boltbio.com

    https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-enrolls-first-patient-phase-2-clinical

    WEBNews Release Details. REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2 clinical trial investigating BDC-1001, a HER2 ...

    DA: 73 PA: 65 MOZ Rank: 2

  • Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data

    boltbio.com

    https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-reports-interim-bdc-1001-phase-12-data

    WEBREDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today …

    DA: 24 PA: 34 MOZ Rank: 84

  • News Releases - Bolt Biotherapeutics

    boltbio.com

    https://investors.boltbio.com/news-and-events/news-releases/

    WEBMarch 21, 2024. Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update. – BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in …

    DA: 10 PA: 56 MOZ Rank: 9

  • Our Science - Bolt Biotherapeutics

    boltbio.com

    https://www.boltbio.com/immuno-oncology-platforms/

    WEBOur Science - Bolt Biotherapeutics. Approach. The majority of the current immunotherapy approaches are focused on the adaptive immune response. Bolt is seeking to successfully engage the innate immune system that will ultimately trigger the adaptive immune system to generate a robust anti-tumor immune response.

    DA: 4 PA: 6 MOZ Rank: 45

  • Bolt Biotherapeutics Presents Updated Clinical Data from Phase …

    boltbio.com

    https://investors.boltbio.com/news-releases/news-release-details/bolt-biotherapeutics-presents-updated-clinical-data-phase-1-dose

    WEBREDWOOD CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated data from its Phase 1 dose-escalation trial of BDC-1001 at the European Society for Medical Oncology (ESMO) 2023 Congress ...

    DA: 13 PA: 39 MOZ Rank: 54